Concert Infectious Disease: Gastroenterologic Testing (Multiplex GI Panels and H. pylori testing) lab
Customize your policy alerts
Sign up for Arizona Complete Health Policy CG.CP.MP.04 alerts
Get alerted when Policy CG.CP.MP.04 changes without checking for updates manually.
Monitor payer policy activity
Outpatient policy governing appropriate use and coding of multiplex gastrointestinal pathogen panels and Helicobacter pylori diagnostic tests for Arizona Complete Health members; affects ordering providers and billing/coding for GI infectious disease testing.
Added 'lab' to title.
Removed CPT and ICD-10 codes from policy reference table.
Added CPT code table and moved the 'coding implications' section.
Corrected coding descriptions in CPT table; removed 0369U and corrected policy number.
For Syndromic/Multiplex Gastrointestinal Pathogen Panels with 11 or Fewer Targets: Changed policy statement from 'may be considered medically necessary' to 'are considered medically necessary.'
Added 87650 and 0369U to Coding Table.
Coverage Criteria
Medically Necessary Criteria — 1-target panels
Syndromic Multiplex Gastrointestinal Pathogen Panels with 11 or Fewer Targets — Covered when ALL of the following are met:
Setting
- Clinical features (at least one): Immunocompromised status (e.g., HIV/AIDS, immunosuppression therapy, primary immunodeficiency) OR recent travel to/contact with travelers from an infectious diarrheal disease-endemic area OR dysentery (presence of blood or mucus in stool) OR fever OR dehydration OR abdominal pain/tenderness OR bacteremia OR diarrhea persisting longer than 7 days OR symptoms of enteric fever (i.e., Typhoid/paratyphoid fever).at least 1 of listed
- Impact on management: Results of the testing will influence the member/enrollee's clinical management.
Medically Necessary Criteria — 12-target panels
Syndromic Multiplex Gastrointestinal Pathogen Panels with 12 or More Targets — Covered when ALL of the following are met:
Setting
- Clinical features (at least one): Immunocompromised status (e.g., HIV/AIDS, immunosuppression therapy, primary immunodeficiency) OR recent travel to/contact with travelers from an infectious diarrheal disease-endemic area OR bacteremia OR symptoms of enteric fever (i.e., Typhoid/paratyphoid fever).at least 1 of listed
- Impact on management: Results of the testing will influence the member/enrollee's clinical management.
Medically Necessary Criteria — H. pylori antigen/urea breath
H. pylori urea breath or stool antigen tests — Covered when ANY one of the following groups of conditions is met:
Syndromic/Multiplex GI Path Panels (<=11 targets) 2 policy change
Policy statement change noted for small-panel syndromic testing
Policy text changed from 'may be considered medically necessary' to 'are considered medically necessary.'
Panels and H. pylori antigen/urea breath tests are covered only for the specific outpatient clinical indications listed in this policy. All other uses are considered investigational and are not covered. This includes multiplex gastrointestinal pathogen panels and H. pylori tests when used for indications not enumerated in the medically necessary criteria (for example, uses outside the listed immunocompromised, travel-related, dysentery, febrile, prolonged-diarrhea, or other specified conditions), and H. pylori antibody tests for any indication are explicitly investigational.
During recent policy updates the reference table organization was changed: CPT and ICD-10 codes were removed from the policy reference table and an explicit CPT code table was added to the policy. Coding descriptions were corrected and one previously listed unique code (0369U) was removed; providers and billing staff should use the updated CPT code table when selecting codes for prior authorization and claims submission.
Helicobacter pylori antibody tests are considered investigational for all indications and are not covered.
This document does not present additional explicit "not medically necessary" condition lists beyond the investigational statements above; operational changes focused on the coding table reorganization and wording clarifications rather than adding new NMN conditions in this excerpt.
Coding and Billing
| 83013 | Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (eg, C-13). |
| 83014 | Helicobacter pylori; drug administration. |
| 86677 | Antibody; Helicobacter pylori. |
| 87338 | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Helicobacter pylori, stool. |
| 87339 | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; Helicobacter pylori. |
| 87493 | Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique. |
| 87498 | Infectious agent detection by nucleic acid (DNA or RNA); enterovirus, amplified probe technique, includes reverse transcription when performed. |
| 87500 | Infectious agent detection by nucleic acid (DNA or RNA); vancomycin resistance (eg, enterococcus species van A, van B), amplified probe technique. |
| 87505 | Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, multiple types or subtypes. |
| 87506 | transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets. |
| 87506 | transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets. |
| 87507 | Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets. |
| 87551 | Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, amplified probe technique. |
| 87556 | Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique. |
| 87561 | Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria avium-intracellulare, amplified probe technique. |
| 87650 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, direct probe technique. |
| 87651 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique. |
| 87652 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, quantification. |
| 87653 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group B, amplified probe technique. |
| 87797 | Infectious agent detection by nucleic acid (DNA or RNA); not otherwise specified; direct probe technique, each organism. |
| 87798 | Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism. |
| 87799 | Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism. |
| 87800 | Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique. |
| 87801 | Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique. |
| 0369U | Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique (unique/recent code referenced). |
Provider Actions and Documentation Requirements
Provide PA/supporting documentation to demonstrate medical necessity
Prior authorization or supporting documentation may be required to show that the requested test meets the policy's medically necessary criteria for the listed CPT/PLA codes for GI pathogen panels and H. pylori testing. Ensure PA (or accompanying documentation) demonstrates outpatient presentation, the applicable clinical features (e.g., immunocompromised status, recent travel, dysentery, fever, dehydration, abdominal pain, bacteremia, diarrhea >7 days, or symptoms of enteric fever) and that test results will influence management.
- PA should reference the specific CPT/PLA code(s) applicable to the ordered test.
- Include clinical details that map to the policy criteria (see criteria for ≤11-target, ≥12-target panels and H. pylori indications).
Select CPT/unique codes from the updated CPT code table for PA and claims
Use CPT and unique codes from the policy's CPT code table on prior authorization requests and claims; do not rely on codes removed from the reference table. Select codes that match the panel target count (e.g., codes describing 3–5 targets versus 12–25 targets) and the specific test type.
- Match panel target count to the CPT code description (≤11 targets vs 12+ targets guidance in the policy).
- Reference the policy's CPT code table and coding implications when submitting PA or claims.
Document outpatient presentation and qualifying clinical indication
Document the outpatient clinical presentation and the specific clinical indication(s) that meet the policy criteria when ordering multiplex GI panels or H. pylori antigen/urea breath tests to support coverage decisions.
- For GI panels, document setting (outpatient), at least one qualifying clinical feature and that results will influence management.
- For H. pylori antigen/urea breath tests, document the applicable indication group (A–G) per policy.
Record test details and clinical impact in the medical record
Include exact test details and code-selected descriptions on the request and in the medical record so reviewers can confirm the ordered test aligns with policy criteria and the CPT table.
- State the specific test performed (e.g., multiplex GI panel with X targets or H. pylori urea breath/stool antigen).
- When applicable, state how results will influence clinical management.
Retain clinical documentation supporting indication and allowable testing frequency
Maintain documentation showing the outpatient setting, the clinical features that satisfy the applicable coverage criteria, and that testing frequency adheres to policy limits (once per incident or ≤14 days for panels).
- For panels: document that testing is being done for an outpatient with suspected infectious gastroenteritis and at least one qualifying clinical feature; record that test results will impact management.
- For repeat testing: document incident timing to show testing is no more than once per incident or within a 14-day period.
Use the updated CPT code table and coding implications section when selecting codes
Reference and use the policy's updated CPT code table and the 'Coding Implications' section for accurate code descriptions and submission guidance; providers and laboratories should rely on the updated table when selecting codes.
- The policy reorganized coding into a CPT code table and moved the coding implications section—use these updated sections for code selection.
- Verify code descriptions against the policy's CPT table before submitting claims or PA requests.
Ordering tests for indications outside criteria risks denial as investigational
Tests ordered for indications outside the policy's listed medically necessary criteria (for multiplex GI panels and H. pylori urea breath/stool antigen tests) are considered investigational and may be denied.
- Examples of non-covered uses include multiplex panels for indications not listed in the policy and H. pylori antibody testing (investigational for all indications).
- Repeat testing more frequently than once per incident or within 14 days may also trigger denial.
Using removed or mismatched codes may trigger denials or coding corrections
Claims submitted with CPT/unique codes that are not listed in the policy's updated CPT table or that use removed/deprecated codes (for example, codes removed or corrected in the policy such as 0369U) may be denied or returned for coding correction.
- Do not submit claims using codes removed from the policy's coding table; verify the current accepted codes in the policy before billing.
- If a lab or provider previously used a removed code, update to the corresponding current CPT/PLA code in the policy table.
Definitions
Background
Acute gastrointestinal infections are commonly caused by bacteria, viruses, fungi, and parasites. Multiplex molecular panels can detect multiple enteric pathogens simultaneously and are intended to be used in outpatient settings where the clinical presentation suggests infectious gastroenteritis and where test results will influence management. For multiplex panels the policy separates panels by panel target count: panels with 11 or fewer targets and panels with 12 or more targets, with specific clinical indications required for coverage (e.g., immunocompromised status, recent travel to endemic areas, bacteremia, enteric fever symptoms). H. pylori testing by urea breath or stool antigen is covered only for the listed indications (active PUD, MALT lymphoma, post‑resection surveillance, uninvestigated dyspepsia under age 60 without alarm features, initiation of chronic NSAID or low‑dose aspirin therapy in some contexts, unexplained iron deficiency anemia after evaluation, or adult ITP).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.